Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/12/2026, 8:00:46 AM
Content snapshot
{ "session_id": "sess_sda-2026-04-01-gap-v2-68d9c9c1_20260412-080046", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "minimax/MiniMax-M2.7", "action": "synthesize", "content": "\n\n{\n \"ranked_hypotheses\": [\n {\n \"rank\": 1,\n \"title\": \"TDP-43 Liquid-Liquid Phase Separation Dysregulation as Cross-Disease Convergence Point\",\n \"mechanism\": \"Aberrant LLPS of TDP-43 drives formation of pathological condensates with altered material properties, occurring in ALS, FTD, and ~40-55% of AD cases (LATE-NC).\",\n \"target_gene\": \"TARDBP\",\n \"confidence_score\": 0.75,\n \"novelty_score\": 0.55,\n \"feasibility_score\": 0.80,\n \"impact_score\": 0.85,\n \"composite_score\": 0.74,\n \"testable_prediction\": \"CSF p-tau231/TDP-43 ratio will distinguish TDP-43 pathology carriers from pure tauopathy in AD cohorts, enabling patient stratification for LLPS-targeted trials.\",\n \"skeptic_concern\": \"Need to establish that LLPS modifiers (e.g., ATRX, HNRNPA1) meaningfully alter TDP-43 aggregate burden in vivo, not just in vitro.\"\n },\n {\n \"rank\": 2,\n \"title\": \"m6A Epitranscriptomic Rewiring Drives RBP Mislocalization\",\n \"mechanism\": \"METTL3/14 overexpression or ALKBH5/FTO downregulation reshapes m6A landscapes, disrupting reader-protein interactions and trapping FUS/TDP-43 into aberrant condensates.\",\n \"target_gene\": \"METTL3\",\n \"confidence_score\": 0.60,\n \"novelty_score\": 0.80,\n \"feasibility_score\": 0.55,\n \"impact_score\": 0.75,\n \"composite_score\": 0.69,\n \"testable_prediction\": \"AAV-mediated METTL3 knockdown in TDP-43 transgenic mice will reduce RBP aggregate burden and rescue motor/spatial deficits.\",\n \"skeptic_concern\": \"Causal direction unresolved—m6A dysregulation may be a downstream consequence of neuronal loss, not a primary driver.\"\n },\n {\n \"rank\": 3,\n \"title\": \"FUS Mutation-Associated LLPS Vulnerability in Sporadic Disease\",\n \"mechanism\": \"FUS mutations cause constitutive nuclear import defects and cytoplasmic LLPS dysregulation, creating vulnerability to secondary hits (oxidative stress, proteasome inhibition) that precipitate ALS-FTD-AD.\",\n \"target_gene\": \"FUS\",\n \"confidence_score\": 0.65,\n \"novelty_score\": 0.70,\n \"feasibility_score\": 0.60,\n \"impact_score\": 0.65,\n \"composite_score\": 0.66,\n \"testable_prediction\": \"Single-nucleus ATAC-seq will reveal FUS-dependent chromatin accessibility changes in sporadic ALS/FTD neurons, identifying actionable co-factors.\",\n \"skeptic_concern\": \"FUS mutations are rare; generalizability to sporadic disease requires additional mechanistic evidence.\"\n }\n ],\n \"consensus_points\": [\n \"TDP-43 pathology represents the strongest mechanistic convergence point across ALS, FTD, and AD, with LATE-NC affecting substantial AD cohorts\",\n \"RBP dysfunction involves both genetic mutations (FUS, TARDBP) and acquired LLPS dysregulation, suggesting convergent therapeutic targets\",\n \"Phase separation biology is critical for understanding how pharmacologically distinct stressors converge on similar RBP aggregates\"\n ],\n \"dissent_points\": [\n \"Expert prioritizes TDP-43-centric mechanism, whereas Theorist emphasizes m6A epitranscriptomic rewiring as more mechanistically novel and upstream\",\n \"Skeptic challenges causal direction of m6A-RBP relationship, arguing m6A dysregulation may be secondary to neurodegeneration rather than primary driver\"\n ],\n \"debate_summary\": \"All parties agree TDP-43 pathology is the strongest cross-disease convergence point, but Theorist emphasizes upstream m6A epitranscriptomic drivers while Expert prioritizes TDP-43 LLPS modifiers given existing biomarker infrastructure; Skeptic correctly identifies that m6A causality must be established before pursuing it as a primary therapeutic target.\"\n}", "tokens_used": "918" }